Efficacy and safety of eslicarbazepine acetate (BIA 2-093) as adjunctive therapy for refractory partial seizures in children a doublie-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial.

Trial Profile

Efficacy and safety of eslicarbazepine acetate (BIA 2-093) as adjunctive therapy for refractory partial seizures in children a doublie-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Sponsors Bial
  • Most Recent Events

    • 22 Nov 2017 This trial has been completed in Portugal (end date: 24 Aug 2017).
    • 12 Oct 2017 This trial has been completed in Hungary (end date: 24 Aug 2017).
    • 01 Sep 2017 This study is completed in Spain - AEMPS according to European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top